BioRx, a specialty pharmacy company, has been named one of a small
number of approved providers of Berinert®. Berinert® is a plasma-derived
concentrate of C1 esterase inhibitor (human) indicated for the treatment
of acute abdominal or facial attacks of hereditary angioedema (HAE) in
adult and adolescent patients. CSL Behring, the manufacturer of
Berinert® selected BioRx as part of their distribution network to launch
this exciting new product in the United States.
BioRx will be launching a dedicated website, www.haefreedom.com,
to provide information about HAE, treatment options, and related BioRx
services.
HAE is a very rare, potentially life threatening genetic condition that
causes episodes of swelling (edema) and fluid retention in various body
parts, including the hands, feet, face, and airway. Patients who have
abdominal attacks can experience episodes of severe pain, diarrhea,
nausea, and vomiting caused by swelling of the intestinal wall. Attacks
that involve the face and larynx can result in airway closure,
asphyxiation, and, if untreated, death.
Diagnosis of HAE requires a blood test to confirm low or abnormal levels
of C1-INH. An estimated 6,000 to 10,000 people in the United Sates have
HAE.
BioRx is one of a limited number of specialty pharmacies selected by CSL
Behring to dispense Berinert ®, which was just recently approved by the
US Food and Drug Administration (FDA) for the treatment of adult and
adolescent patients
with acute abdominal or facial attacks of HAE. CSL Behring manufactures
and sells C1-INH concentrate in Germany, Austria, Switzerland, and
several other countries under the trade name Berinert P®.
Mark Kestler, General Manager of BioRx, says “Recognition by CSL Behring
as an approved Berinert® provider validates BioRx as a leading quality
provider of specialized pharmaceutical services. We are excited to be
able to offer this valuable treatment option to HAE patients.”
SOURCE BioRx